Eris Lifesciences Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
1370.85 +6.45 (0.47%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1350
Today’s High
1391.7
52 Week Low
810.1
52 Week High
1521.05
1366.90 -1.55 (-0.11%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1349.35
Today’s High
1376.75
52 Week Low
809.15
52 Week High
1522.05
Key Metrics
- Market Cap (In Cr) 18625.4
- Beta 0.73
- Div. Yield (%) 0
- P/B 7.2
- TTM P/E 52.04
- Peg Ratio 16.35
- Sector P/E 31.15
- D/E 0.99
- Open Price 1391.7
- Prev Close 1364.4
Eris Lifesciences Analysis
Price Analysis
-
1 Week3.4%
-
3 Months13.12%
-
6 Month50.72%
-
YTD50.38%
-
1 Year49.23%
Risk Meter
- 30% Low risk
- 30% Moderate risk
- 30% Balanced Risk
- 30% High risk
- 30% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 4
- 4
- 4
- 5
- Buy
- 3
- 3
- 3
- 2
- Hold
- 1
- 1
- 1
- 1
- Sell
- 0
- 0
- 0
- 0
- Strong Sell
- 0
- 0
- 0
- 0
- Total
- 8
- 8
- 8
- 8
Eris Lifesciences News
Home remedy: Indian pharma bets on domestic brands to fight US generics slowdown
4 min read . 08 Nov 2024Diwali 2024 stock picks: Ashika Group recommends 7 stocks with up to 33% upside
6 min read . 21 Oct 2024Prizor Viztech, Cadsys (India) & others hit 52 week low today ;Check the full list here?
3 min read . 04 Sep 2024Eris Lifesciences Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 2009.14
- Selling/ General/ Admin Expenses Total
- 403.82
- Depreciation/ Amortization
- 182.6
- Other Operating Expenses Total
- 550.45
- Total Operating Expense
- 1516.92
- Operating Income
- 492.22
- Net Income Before Taxes
- 431.24
- Net Income
- 391.98
- Diluted Normalized EPS
- 28.79
- Period
- 2024
- Total Assets
- 7048.84
- Total Liabilities
- 4462.72
- Total Equity
- 2586.12
- Tangible Book Valueper Share Common Eq
- -90.97
- Period
- 2024
- Cashfrom Operating Activities
- 486.01
- Cashfrom Investing Activities
- -1854.52
- Cashfrom Financing Activities
- 1379.78
- Net Changein Cash
- 11.26
- Period
- 2023
- Total Revenue
- 1685.15
- Selling/ General/ Admin Expenses Total
- 747.48
- Depreciation/ Amortization
- 117.09
- Other Operating Expenses Total
- 26.92
- Total Operating Expense
- 1263.49
- Operating Income
- 421.66
- Net Income Before Taxes
- 404.64
- Net Income
- 382.16
- Diluted Normalized EPS
- 28.2
- Period
- 2023
- Total Assets
- 3667.33
- Total Liabilities
- 1471.34
- Total Equity
- 2195.99
- Tangible Book Valueper Share Common Eq
- -1.21
- Period
- 2023
- Cashfrom Operating Activities
- 299.23
- Cashfrom Investing Activities
- -982.1
- Cashfrom Financing Activities
- 688.02
- Net Changein Cash
- 5.15
- Period
- 2022
- Total Revenue
- 1347.04
- Selling/ General/ Admin Expenses Total
- 535.07
- Depreciation/ Amortization
- 64.7
- Other Operating Expenses Total
- 23.7
- Total Operating Expense
- 922.54
- Operating Income
- 424.5
- Net Income Before Taxes
- 442.2
- Net Income
- 406.11
- Diluted Normalized EPS
- 30.17
- Period
- 2022
- Total Assets
- 2272.14
- Total Liabilities
- 363.83
- Total Equity
- 1908.31
- Tangible Book Valueper Share Common Eq
- 84.99
- Period
- 2022
- Cashfrom Operating Activities
- 378.26
- Cashfrom Investing Activities
- -319.61
- Cashfrom Financing Activities
- -44.7
- Net Changein Cash
- 13.96
- Period
- 2021
- Total Revenue
- 1211.86
- Selling/ General/ Admin Expenses Total
- 496.46
- Depreciation/ Amortization
- 42.98
- Other Operating Expenses Total
- 32.77
- Total Operating Expense
- 824.25
- Operating Income
- 387.61
- Net Income Before Taxes
- 394.5
- Net Income
- 355.14
- Diluted Normalized EPS
- 26.14
- Period
- 2021
- Total Assets
- 1834.78
- Total Liabilities
- 258.36
- Total Equity
- 1576.42
- Tangible Book Valueper Share Common Eq
- 58.84
- Period
- 2021
- Cashfrom Operating Activities
- 375.36
- Cashfrom Investing Activities
- -323.36
- Cashfrom Financing Activities
- -82.4
- Net Changein Cash
- -30.39
- Period
- 2020
- Total Revenue
- 1074.06
- Selling/ General/ Admin Expenses Total
- 511.55
- Depreciation/ Amortization
- 50.26
- Other Operating Expenses Total
- 1.19
- Total Operating Expense
- 752.21
- Operating Income
- 321.85
- Net Income Before Taxes
- 331.35
- Net Income
- 296.5
- Diluted Normalized EPS
- 21.84
- Period
- 2020
- Total Assets
- 1552.3
- Total Liabilities
- 255.97
- Total Equity
- 1296.33
- Tangible Book Valueper Share Common Eq
- 37.15
- Period
- 2020
- Cashfrom Operating Activities
- 271.11
- Cashfrom Investing Activities
- 123.29
- Cashfrom Financing Activities
- -334.59
- Net Changein Cash
- 59.81
- Period
- 2019
- Total Revenue
- 982.16
- Selling/ General/ Admin Expenses Total
- 470.79
- Depreciation/ Amortization
- 36.35
- Other Operating Expenses Total
- 1.78
- Total Operating Expense
- 673.28
- Operating Income
- 308.88
- Net Income Before Taxes
- 317.36
- Net Income
- 290.8
- Diluted Normalized EPS
- 21.15
- Period
- 2019
- Total Assets
- 1553.66
- Total Liabilities
- 403.14
- Total Equity
- 1150.52
- Tangible Book Valueper Share Common Eq
- 32.24
- Period
- 2019
- Cashfrom Operating Activities
- 223
- Cashfrom Investing Activities
- -5.05
- Cashfrom Financing Activities
- -221.05
- Net Changein Cash
- -3.11
- Period
- 2018
- Total Revenue
- 855.6
- Selling/ General/ Admin Expenses Total
- 384.79
- Depreciation/ Amortization
- 25.64
- Other Operating Expenses Total
- 1.12
- Total Operating Expense
- 559.22
- Operating Income
- 296.38
- Net Income Before Taxes
- 312.23
- Net Income
- 294.1
- Diluted Normalized EPS
- 21.39
- Period
- 2018
- Total Assets
- 1460.08
- Total Liabilities
- 598.78
- Total Equity
- 861.31
- Tangible Book Valueper Share Common Eq
- 10.39
- Period
- 2018
- Cashfrom Operating Activities
- 235.15
- Cashfrom Investing Activities
- -590.1
- Cashfrom Financing Activities
- 363.21
- Net Changein Cash
- 8.26
- Period
- 2024-09-30
- Total Revenue
- 741.17
- Selling/ General/ Admin Expenses Total
- 125.63
- Depreciation/ Amortization
- 80.48
- Other Operating Expenses Total
- 164.76
- Total Operating Expense
- 557.14
- Operating Income
- 184.03
- Net Income Before Taxes
- 129.11
- Net Income
- 91.59
- Diluted Normalized EPS
- 6.72
- Period
- 2024-09-30
- Total Assets
- 7021.88
- Total Liabilities
- 4250.41
- Total Equity
- 2771.47
- Tangible Book Valueper Share Common Eq
- -147.79
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 485.1
- Cashfrom Investing Activities
- -82.44
- Cashfrom Financing Activities
- -346.89
- Net Changein Cash
- 55.77
- Period
- 2024-06-30
- Total Revenue
- 719.72
- Selling/ General/ Admin Expenses Total
- 132.62
- Depreciation/ Amortization
- 75.94
- Other Operating Expenses Total
- 156.52
- Total Operating Expense
- 545.67
- Operating Income
- 174.05
- Net Income Before Taxes
- 115.32
- Net Income
- 83.18
- Diluted Normalized EPS
- 6.1
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 550.92
- Selling/ General/ Admin Expenses Total
- 102.48
- Depreciation/ Amortization
- 53.9
- Other Operating Expenses Total
- 181.83
- Total Operating Expense
- 456.39
- Operating Income
- 94.53
- Net Income Before Taxes
- 76.65
- Net Income
- 70.96
- Diluted Normalized EPS
- 5.21
- Period
- 2024-03-31
- Total Assets
- 7048.84
- Total Liabilities
- 4462.72
- Total Equity
- 2586.12
- Tangible Book Valueper Share Common Eq
- -90.97
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 486.01
- Cashfrom Investing Activities
- -1854.52
- Cashfrom Financing Activities
- 1379.78
- Net Changein Cash
- 11.26
- Period
- 2023-12-31
- Total Revenue
- 486.3
- Selling/ General/ Admin Expenses Total
- 98.68
- Depreciation/ Amortization
- 45.72
- Other Operating Expenses Total
- 123.24
- Total Operating Expense
- 356.5
- Operating Income
- 129.79
- Net Income Before Taxes
- 115.87
- Net Income
- 102.74
- Diluted Normalized EPS
- 7.54
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 505.3
- Selling/ General/ Admin Expenses Total
- 98.53
- Depreciation/ Amortization
- 42.09
- Other Operating Expenses Total
- 131.03
- Total Operating Expense
- 366.25
- Operating Income
- 139.05
- Net Income Before Taxes
- 126.24
- Net Income
- 123.43
- Diluted Normalized EPS
- 9.06
- Period
- 2023-09-30
- Total Assets
- 3875.19
- Total Liabilities
- 1463.62
- Total Equity
- 2411.57
- Tangible Book Valueper Share Common Eq
- 18.83
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 264.28
- Cashfrom Investing Activities
- -55.35
- Cashfrom Financing Activities
- -92.24
- Net Changein Cash
- 116.69
- Period
- 2023-06-30
- Total Revenue
- 466.62
- Selling/ General/ Admin Expenses Total
- 104.13
- Depreciation/ Amortization
- 40.89
- Other Operating Expenses Total
- 114.35
- Total Operating Expense
- 337.77
- Operating Income
- 128.85
- Net Income Before Taxes
- 112.48
- Net Income
- 94.85
- Diluted Normalized EPS
- 6.97
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 402.8
- Selling/ General/ Admin Expenses Total
- 85.81
- Depreciation/ Amortization
- 35.13
- Other Operating Expenses Total
- 125.34
- Total Operating Expense
- 319.03
- Operating Income
- 83.76
- Net Income Before Taxes
- 75.9
- Net Income
- 65.42
- Diluted Normalized EPS
- 4.79
- Period
- 2023-03-31
- Total Assets
- 3667.33
- Total Liabilities
- 1471.34
- Total Equity
- 2195.99
- Tangible Book Valueper Share Common Eq
- -1.21
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 299.23
- Cashfrom Investing Activities
- -982.1
- Cashfrom Financing Activities
- 688.02
- Net Changein Cash
- 5.15
- Period
- 2022-12-31
- Total Revenue
- 423.26
- Selling/ General/ Admin Expenses Total
- 87
- Depreciation/ Amortization
- 29.9
- Other Operating Expenses Total
- 110.27
- Total Operating Expense
- 315.95
- Operating Income
- 107.3
- Net Income Before Taxes
- 106.54
- Net Income
- 101.86
- Diluted Normalized EPS
- 7.49
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Eris Lifesciences Technical
Moving Average
SMA
- 5 Day1346.26
- 10 Day1326.44
- 20 Day1313.21
- 50 Day1348.28
- 100 Day1239.4
- 300 Day1072.53
Eris Lifesciences Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Alembic Pharmaceuticals
- 1038.4
- -4.2
- -0.4
- 1296.15
- 710.5
- 20411.11
- Wockhardt
- 1158.2
- -28.75
- -2.42
- 1334.55
- 321
- 17836.28
- Eris Lifesciences
- 1370.85
- 6.45
- 0.47
- 1521.05
- 810.1
- 18647.44
- Jubilant Pharmova
- 1140
- 8.9
- 0.79
- 1309
- 408.6
- 18051.98
- Caplin Point Laboratories
- 1941.95
- -9.35
- -0.48
- 2175
- 1179.95
- 14747.51
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Alembic Pharmaceuticals
- 33.3
- 4.24
- 15.94
- 12.47
- Wockhardt
- -
- 5.41
- -10.63
- -12.7
- Eris Lifesciences
- 47.3
- 7.2
- 20.71
- 24.96
- Jubilant Pharmova
- 120.43
- 3.29
- 6.15
- 5.13
- Caplin Point Laboratories
- 32.55
- 6.4
- 22.81
- 25.39
Eris Lifesciences Shareholding
Shareholding Pattern
*Promoter pledging: 10.16%
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 25-Oct-24
- Quarterly Results
- 02-Aug-24
- Quarterly Results
- 21-May-24
- Audited Results & Fund Raising
- 13-Feb-24
- Quarterly Results
- 08-Nov-23
- Quarterly Results
- 07-Aug-23
- Quarterly Results
- 17-May-23
- Audited Results
- 17-Jan-23
- Quarterly Results
- 20-Oct-22
- Quarterly Results
- 05-Aug-22
- Quarterly Results & Interim Dividend
- Meeting Date
- Announced on
- Purpose
- 25-Sept-24
- 04-Sept-24
- AGM
- 25-Sept-23
- 08-Sept-23
- AGM
- 01-Sept-21
- 29-Jul-21
- AGM
- 26-Jul-21
- 22-Jun-21
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 02-Aug-22
- 16-Aug-22
- 11-Aug-22
- 7.35
- 26-Jul-21
- 06-Aug-21
- 05-Aug-21
- 6.01